Fasting plasma glucose level in the range of 90–99 mg/dL and the risk of the onset of type 2 diabetes: Population-based Panasonic cohort study

Chihiro Munekawa1, Hiroshi Okada2*, Masahide Hamaguchi1, Momoko Habu2, Kazushiro Kurogi3, Hiroaki Murata4, Masato Ito3, Michiaki Fukui1

1Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, 2Department of Diabetes and Endocrinology, Matsushita Memorial Hospital, Moriguchi, Japan, 3Department of Health Care Center, Panasonic Health Insurance Organization, Moriguchi, Japan, and 4Department of Orthopaedic Surgery, Matsushita Memorial Hospital, Moriguchi, Japan

Keywords
Database research, Fasting plasma glucose level, Type 2 diabetes

*Correspondence
Hiroshi Okada
Tel: +81-6-6992-1231
Fax: +81-6-6992-4845
E-mail address: continental4x33211@msn.com

J Diabetes Investig 2022; 13: 453–459
doi: 10.1111/jdi.13692

ABSTRACT

Aim/Introduction: As the association between a fasting glucose concentration of 90–99 mg/dL and the onset of type 2 diabetes is still controversial, we aimed to assess it in 37,148 Japanese individuals with a normal plasma glucose concentration.

Materials and Methods: This long-term retrospective cohort study included individuals having a medical checkup at Panasonic Corporation from 2008 to 2018. In total, 1,028 participants developed type 2 diabetes.

Results: Cox regression analyses revealed that the risk for the onset of diabetes increased by 9.0% per 1 mg/dL increase in fasting plasma glucose concentration in subjects with the concentration ranging from 90 to 99 mg/dL. Compared with individuals with a fasting glucose concentration of ≤89 mg/dL, the adjusted hazard ratios for developing diabetes were 1.53 (95% CI; 1.22–1.91), 1.76 (95% CI; 1.41–2.18), 1.89 (95% CI; 1.52–2.35), 3.17 (95% CI; 2.61–3.84), and 3.41 (95% CI; 2.79–4.15) at fasting plasma glucose concentrations of 90–91, 92–93, 94–95, 96–97, and 98–99 mg/dL, respectively. In populations with obesity, the adjusted hazards ratios for developing diabetes were 1.56 (95% CI; 1.15–2.09), 1.82 (95% CI; 1.37–2.40), 2.05 (95% CI; 1.55–2.69), 3.53 (95% CI; 2.79–4.46), and 3.28 (95% CI; 2.53–4.22) at fasting plasma glucose concentrations of 90–91, 92–93, 94–95, 96–97, and 98–99 mg/dL, respectively.

Conclusions: This study demonstrates that the risk of type 2 diabetes among subjects having a fasting plasma glucose concentration of 90–99 mg/dL, is progressively higher with an increasing level of fasting plasma glucose concentration in a Japanese people.

INTRODUCTION

The presence of diabetes and the medical costs of diabetes have been increasing worldwide, recently. Therefore, one of the goals in clinical care is to prevent the onset of diabetes. In the Japanese population, several risk factors, for example, age, obesity, smoking history, hypertension, impaired glucose tolerance, impaired fasting glucose (IFG), hyperlipidemia, and family history are well known risks for the onset of diabetes1–7.

Impaired fasting glucose is defined as a fasting glucose concentration of 100–125 mg/dL (5.6–6.9 mmol/L) in the United States8–10. On the other hand, the World Health Organization and the Japanese Diabetes Association define the cutoff for IFG as 110 mg/dL (6.1 mmol/L)8,11. The Japan Diabetes Society defined high-normal glycemia as a fasting glucose concentration of 100–109 mg/dL11. Several studies have assessed the association between normal plasma glucose and the onset of type 2 diabetes in the Japanese people. It has been reported that not only a concentration of fasting plasma glucose 100–109 mg/dL...
but also 95–99 mg/dL represent a risk for developing diabetes. Conversely, Kabeya et al. suggested that a fasting plasma glucose concentration of 90–99 mg/dL did not relate to the onset of diabetes. Thus, the association between a fasting plasma glucose concentration of 90–99 mg/dL and developing type 2 diabetes remains controversial. The underlying reasons for the conflicting results of previous studies are differences in sample size, study duration, age, and covariates. Previous studies were based on relatively small samples, had short follow-up periods, or were focused on the elderly population.

To our knowledge, the association between normal plasma glucose and the onset of type 2 diabetes in Japanese people is still controversial. Thus, this is the first study to investigate the association between a normal concentration of plasma glucose and developing type 2 diabetes in a large Japanese population and long follow-up periods.

MATERIALS AND METHODS

Study design and data collection

This is a retrospective cohort study including participants who worked at Panasonic Corporation, Osaka, Japan, and underwent a physical examination program. This study used the database of the Panasonic cohort study from 2008 to 2018. The Panasonic cohort study is described in detail elsewhere. All participants received a blood examination every year. The baseline characteristics were assessed using a self-administered questionnaire, which was standardized and has been previously validated. The participants were classified as non-smokers, past smokers, and current smokers. Eating speed was classified as fast, normal, and slow. The participants were asked about their habits of breakfast and snacks after dinner. The participants who consumed alcohol daily were classified as alcohol drinkers. The participants who practiced any sport twice a week regularly were classified as regular exercisers. The definition of type 2 diabetes was followed as a fasting plasma glucose concentration of ≥126 mg/dL, taking an anti-diabetic medication, and/or having a self-reported history of diabetes.

The study was approved by the local ethics committee of Panasonic Health Insurance Organization (Approval number: 2021-001) and was conducted in accordance with the principles of the Declaration of Helsinki.

Exclusion criteria

In all, 140,590 employees underwent a physical examination program in 2008. We excluded participants from the study who did not undergo the physical examination program consecutively from 2008 to 2018 (n = 65,256), who had been diagnosed with diabetes at baseline (n = 4,342), who had a fasting plasma glucose concentration of ≥100–125 mg/dL at baseline (n = 8,853), and those with missing data (n = 24,991).

Statistical analyses

The differences in the general characteristics at baseline according to the onset of diabetes at follow-up and the glucose concentration at baseline (glucose ≤89 mg/dL and ≥90 mg/dL) were evaluated by Mann–Whitney U test and chi-square test as appropriate. The fasting plasma glucose concentrations were divided into six groups to evaluate the relation between the onset of type 2 diabetes and fasting plasma glucose concentration: ≤89, 90–91, 92–93, 94–95, 96–97, and 98–99 mg/dL. The association between fasting plasma glucose concentration and the onset of type 2 diabetes was assessed by Cox regression analyses. The continuous variable of fasting plasma glucose concentration and the six groups according to fasting plasma glucose concentration were added to the multivariate models 1 and 2, respectively. The multivariate analysis was adjusted for the factors related to the onset of type 2 diabetes such as age, sex, BMI, levels of triglycerides, levels of high-density lipoprotein (HDL) cholesterol, levels of low-density lipoprotein (LDL) cholesterol, levels of uric acid, systolic blood pressure (SBP), smoking status, eating speed, the habit of snacks after dinner, the habit of breakfast, alcohol consumption, and the habit of physical exercise. We also assessed the association between fasting plasma glucose concentration and the onset of type 2 diabetes in patients with obesity (BMI ≥25 kg/m²) at baseline who had a high risk of developing diabetes. A receiver operating characteristic curve analysis was performed for the fasting plasma glucose concentration to assess its ability to identify the onset of type 2 diabetes. Statistical analyses of this study were performed using JMP software (SAS Institute, NC, USA). The continuous variables are presented as the mean ± standard deviation or as absolute numbers. We defined differences with a P value < 0.05 as statistically significant. The associations are presented as hazard ratios with 95% confidence intervals (CI).

RESULTS

Tables 1 and 2 show the baseline characteristics of all participants in this study. In total, 1,028 participants developed type 2 diabetes in the study. Table 3 shows the unadjusted hazard ratios for the onset of diabetes.

Table 4 shows the adjusted hazard ratios in multivariate models for the onset of diabetes. For every 1 mg/dL increase in the concentration of fasting glucose, the risk of developing diabetes increased by 9.0% (model 1). The risk of developing type 2 diabetes was higher at fasting plasma glucose concentrations of 90–91, 92–93, 94–95, 96–97, and 98–99 mg/dL than at a concentration of ≤89 mg/dL. The adjusted hazard ratios for the onset of diabetes were 1.53 (95% CI; 1.22–1.91), 1.76 (95% CI; 1.41–2.18), 1.89 (95% CI; 1.52–2.35), 3.17 (95% CI; 2.61–3.84), and 3.41 (95% CI; 2.79–4.15) at fasting plasma glucose concentrations of 90–91, 92–93, 94–95, 96–97, and 98–99 mg/dL, respectively (model 2). Age, BMI, SBP, triglycerides, HDL cholesterol, LDL cholesterol, current smoking habits, alcohol consumption, eating speed, and skipping breakfast were also related with developing type 2 diabetes.

Tables 5 and 6 show the incidence rate (per 1000 person-year) and the adjusted hazard ratios for the onset of diabetes in multivariate models in all populations and in subjects with...
obesity (BMI ≥ 25 kg/m²). The adjusted hazard ratios for the onset of diabetes in subjects with obesity were 1.56 (95% CI; 1.15–2.09), 1.82 (95% CI; 1.37–2.40), 2.05 (95% CI; 1.55–2.69), 3.53 (95% CI; 2.79–4.46), and 3.28 (95% CI; 2.53–4.22) at fasting plasma glucose concentrations of 90–91, 92–93, 94–95, 96–97, and 98–99 mg/dL, respectively.

The cut-off value of fasting plasma glucose concentration to identify the onset of type 2 diabetes was 92 mg/dL or 90 mg/dL in all populations or in subjects with obesity (BMI ≥ 25 kg/m²). When all subjects with a fasting plasma glucose concentration of 100–125 mg/dL at baseline were included, the cut-off value of fasting plasma glucose concentration was 99 mg/dL or 101 mg/dL in all the population or in subjects with obesity (BMI ≥ 25 kg/m²).

**DISCUSSION**
In this study, a fasting plasma glucose in the range of 90–99 mg/dL was related with increased odds of developing type 2 diabetes.

### Table 1 | Characteristics of participants at baseline

| Characteristics of participants at baseline | Development of diabetes (–) | Development of diabetes (+) | P value |
|---------------------------------------------|-----------------------------|-----------------------------|--------|
| N                                           | 37,148                      | 36,120                      | 1,028  |
| Age (year)                                  | 41.59 (6.17)                | 41.55 (6.18)                | 42.89 (5.80) | <0.0001 |
| Sex (male/female)                           | 30,262/6,886                | 29,336/6,784                | 926/102 | <0.0001 |
| BMI (kg/m²)                                 | 22.80 (3.17)                | 22.72 (3.09)                | 25.84 (4.12) | <0.0001 |
| SBP (mmHg)                                  | 117.14 (13.52)              | 116.95 (13.41)              | 124.06 (15.29) | <0.0001 |
| DBP (mmHg)                                  | 73.13 (10.42)               | 72.99 (10.37)               | 78.0 (11.21) | <0.0001 |
| LDL cholesterol (mg/dL)                     | 122.13 (30.55)              | 121.81 (30.41)              | 133.39 (33.39) | <0.0001 |
| HDL cholesterol (mg/dL)                     | 89.44 (5.91)                | 89.35 (5.90)                | 92.69 (5.34) | <0.0001 |
| Glucose (mg/dL)                             | 5.79 (1.37)                 | 5.77 (1.37)                 | 6.29 (1.33) | <0.0001 |
| Smoking (none/past/current)                 | 19,233/4,547/13,368         | 18,873/4,428/12,819         | 360/119/549 | <0.0001 |
| Eating speed (fast/normal/slow)             | 12,490/22,024/2,634         | 12,033/21,484/2,603         | 457/540/31 | <0.0001 |
| Snack after dinner (+/–)                    | 6,513/30,635                | 6,339/29,781                | 174/854  | 0.62 |
| Skipping breakfast (+/–)                    | 8,353/28,795                | 8,038/28,082                | 315/713  | <0.0001 |
| Alcohol drinker (+/–)                       | 8,432/28,716                | 8,243/27,877                | 189/859  | 0.001 |
| Physical exercise (+/–)                     | 5,543/31,605                | 5,388/30,732                | 155/873  | 0.86 |

Data are presented as mean (standard deviation) or absolute number. BMI, body mass index; DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure.

### Table 2 | Characteristics of participants at baseline according to glucose level

| Glucose ≤ 89 mg/dL | Glucose ≥ 90 mg/dL | P value |
|--------------------|--------------------|--------|
| N                  | 17,636             | 19,512 | – |
| Age (year)         | 40.65 (6.40)       | 42.44 (5.83) | <0.0001 |
| Sex (male/female)  | 13,345/4,291       | 16,917/2595 | <0.0001 |
| Body mass index (kg/m²) | 22.32 (3.07) | 23.24 (3.19) | <0.0001 |
| Systolic blood pressure (mmHg) | 114.95 (13.14) | 119.13 (13.54) | <0.0001 |
| Diastolic blood pressure (mmHg) | 71.48 (10.24) | 74.62 (10.36) | <0.0001 |
| LDL cholesterol (mg/dL) | 118.84 (30.32) | 125.11 (30.46) | <0.0001 |
| HDL cholesterol (mg/dL) | 61.13 (15.14) | 58.63 (14.52) | <0.0001 |
| Triglycerides (mg/dL) | 100.63 (77.67) | 116.43 (87.74) | <0.0001 |
| Glucose (mg/dL)    | 84.39 (4.04)       | 94.01 (2.79) | <0.0001 |
| Uric acid (mg/dL)  | 5.61 (1.37)        | 5.95 (1.35) | <0.0001 |
| Smoking (none/past/current) | 9,124/1,860/6,652 | 10,109/2,687/6,716 | <0.0001 |
| Eating speed (fast/normal/slow) | 5,746/10,604/1,286 | 6,744/11,420/1,348 | 0.0003 |
| Snack after dinner (+/–) | 3,132/14,504 | 3,381/16,131 | 0.28 |
| Skipping breakfast (+/–) | 3,955/1,368 | 4,398/15,114 | 0.80 |
| Alcohol drinker (+/–) | 3,501/1,435 | 4,931/14,581 | <0.0001 |
| Physical exercise (+/–) | 2,524/15,112 | 3,019/16,493 | 0.002 |

Data are presented as mean (standard deviation) or absolute number. HDL, high-density lipoprotein; LDL, low-density lipoprotein.
diabetes. The effects observed were almost the same as in subjects with obesity. Our study indicates that hazard ratios for the onset of type 2 diabetes, among the subjects having fasting plasma glucose concentration of 90–99 mg/dL with or without obesity, is progressively higher with an increasing level of fasting plasma glucose concentration.

The Japan Diabetes Society defined high-normal glycemia as a fasting glucose concentration of 100–109 mg/dL, and individuals with a concentration of glucose in this range have a high risk of diabetes. There are few studies that have evaluated the association between fasting blood glucose concentration in the normal range and the onset of type 2 diabetes. The association between a fasting glucose concentration of 90–99 mg/dL and the onset of type 2 diabetes is still controversial. Kato et al. reported that a fasting glucose concentration of 100–109 mg/dL imposes a substantial risk for the onset of diabetes and a fasting glucose concentration of 95–99 mg/dL was found to be related with an increased hazard ratio only in women. Their study followed 2,207 subjects who were recruited from public health center annual health examinations during 5 years. In their study, type 2 diabetes was defined using the fasting plasma glucose concentration, HbA1c, and self-reported history of diabetes and they used the data including every socioeconomic status in the elderly population. Considering that Japan’s Ministry of Health, Labour and Welfare reported that the risk of diabetes gradually increases from the fourth decade of life, further studies in younger subjects are needed to prevent the onset of diabetes. We believe that the findings of our study may be useful to shed light on the association between fasting glucose concentration in the normal range and in developing diabetes.

It has been proposed that the onset of diabetes is triggered by insulin resistance, which eventually leads to the exhaustion of pancreatic β cells, as shown in studies conducted in Western populations. However, pre-diabetes in a Japanese population is both characterized by lower insulin secretion and lower insulin resistance compared with Western populations. Mitsu et al. reported that insulin secretory defects and decreased insulin sensitivity may occur even in patients with a fasting glucose concentration of 100–109 mg/dL. Moreover, type 2 diabetes is a disease with a very long, silent phase, during which time the plasma glucose is normal but already elevated in those destined to develop diabetes compared with those destined not. Hence, we hypothesize that insulin secretory defects may occur in individuals with a fasting glucose concentration of 90–99 mg/dL. It is important to note that a slight increase in insulin resistance due to body weight gain can easily lead to the onset of type 2 diabetes by disrupting the balance of insulin secretion capacity, which is commonly observed in East Asians.

We should consider the cost of interventions aimed to prevent diabetes in individuals with a fasting glucose concentration of 90–99 mg/dL. If the cutoff value of IFG is lowered, the costs derived from screening and health guidance for the prevention of diabetes would increase markedly. Therefore, we assessed patients with obesity (BMI ≥ 25 kg/m²) at baseline who were likely to develop diabetes and identified subjects at high risk. Our study showed that subjects with a fasting glucose concentration of 90–99 mg/dL and a BMI of ≥ 25 kg/m² are also at risk of developing diabetes. It is considered that subjects with prediabetes often have some risk factors of cardiovascular disease, including dyslipidemia and hypertension, and are at increased risk for cardiovascular disease. Therefore, we suggest that the cutoff value of high-normal glycemia might be reduced to less than 100 mg/dL in individuals with or without obesity.

The strengths of our study include its long follow-up period, large sample size, and consecutive enrolment because this cohort is based on corporation health examinations. However, there are several limitations in this study. First, hemoglobin A1c levels were not considered in the diagnosis of diabetes. Although we did not collect data on HbA1c, the correlation coefficient between HbA1c level and fasting glucose concentration was reported to be 0.85 in a previous study; therefore,
we thought that it was possible to evaluate the onset of diabetes using the fasting glucose concentration. Secondly, medication for hypertension could affect the onset of diabetes. Unfortunately, however, we have no data about the medication for hypertension. Thirdly, an oral glucose tolerance test and insulin level could be useful to diagnose diabetes and to indicate the potential risk for the onset of type 2 diabetes. Unfortunately, however, we have no data about oral glucose tolerance test and insulin level. Finally, the study population consisted of relatively young Japanese men and women with high socioeconomic status, and it is therefore unclear whether the findings of this study are generalizable to other ethnic groups and age categories.

It is important to focus on the fasting glucose concentration in the normal range in Japanese people in clinical settings to reduce the risk of the onset of diabetes. In conclusion, our data indicate that the risk of type 2 diabetes diagnosed by a fasting plasma glucose concentration of \( \geq 126 \) mg/dL, within 10 years, among the subjects having a fasting plasma glucose concentration of 90–99 mg/dL, is progressively higher with increasing level of fasting plasma glucose concentration in a Japanese people.
Table 6 | Multivariate adjusted hazard ratios for development of diabetes in all population and obesity (BMI ≥ 25 kg/m²)

| Glucose | All population | Obesity (BMI ≥ 25 kg/m²) |
|---------|----------------|-------------------------|
|         | HR (95% CI)    | P value | HR (95% CI)    | P value |
| ≤89 mg/dL | 1.00 (0.79–1.28) | 0.840 | 1.00 (0.77–1.28) | 0.965 |
| 90–94 mg/dL | 1.26 (1.06–1.50) | 0.010 | 1.40 (1.18–1.65) | <0.0001 |
| 95–99 mg/dL | 1.44 (1.20–1.75) | <0.0001 | 1.61 (1.34–1.94) | <0.0001 |
| ≥100 mg/dL | 1.80 (1.44–2.25) | <0.0001 | 2.07 (1.69–2.55) | <0.0001 |

ACKNOWLEDGMENTS

We thank Editage (Tokyo, Japan) for the assistance with English editing. We thank Taro Hirozane, Shinta Yamamoto, Nozomi Yoshioka, Akifumi Shioya, and Tomoyuki Matsuyama for their assistance of this study.

DISCLOSURE

Conflict of interest: Dr Okada received personal fees from Eli Lilly, Japan, Ono Pharma Co., Ltd, Sumitomo Dainippon Pharma Co., Ltd, Kissei Pharma Co., Ltd, Mitsubishi Tanabe Pharma Corp., Novo Nordisk Pharma Ltd, Daiichi Sankyo Co., Ltd, Takeda Pharma Co., Ltd, Kowa Pharma Co., Ltd, Kyowa Kirin Co., Ltd, Sanofi K.K and MSD K.K., Dr Hamaguchi received grants from Ono Pharma Co. Ltd, AstraZeneca K.K., Yamada Bee Farm and Oishi Kenko Inc., and received personal fees from Sanofi K.K, Mitsubishi Tanabe Pharma Corp., Ono Pharma Co. Ltd, AstraZeneca K.K., Eli Lilly, Japan, Daiichi Sankyo Co. Ltd, Kowa Pharma Co. Ltd, and Sumitomo Dainippon Pharma Co., Ltd, outside the submitted work. Dr Fukui received grants from Mitsubishi Tanabe Pharma Corp., Ono Pharma Co. Ltd, Terumo Corp., Sanwa Kagaku Kenkyusho Co., Ltd, Yamada Bee Farm, Kowa Pharma Co. Ltd, Nippon Chemiphar Co., Ltd, Nippon Boehringer Ingelheim Co. Ltd, Sumitomo Dainippon Pharma Co., Ltd, Novo Nordisk Pharma Ltd, Oishi Kenko Inc., Sanofi K.K, Daiichi Sankyo Co. Ltd, Kissei Pharma Co. Ltd, Takeda Pharma Co. Ltd, Taisho Pharma Co., Ltd, MSD K.K., Abbott Japan Co. Ltd, Kyowa Kirin Co., Ltd, Eli Lilly, Japan, K.K., Astellas Pharma Inc., Teijin Pharma Ltd, and Johnson & Johnson K.K. Medical Co. and received personal fees from Takeda Pharma Co. Ltd, Sumitomo Dainippon Pharma Co. Ltd, Kissei Pharma Co., Ltd, Kowa Pharma Co. Ltd, Mitsubishi Tanabe Pharma Corp., MSD K.K., Ono Pharma Co. Ltd, AstraZeneca K.K., Novo Nordisk Pharma Ltd, Kyowa Kirin Co. Ltd, Nippon Boehringer Ingelheim Co. Ltd, Astellas Pharma Inc., Mochida Pharma Co. Ltd, Daiichi Sankyo Co. Ltd, Eli Lilly Japan K.K., Sanofi K.K, Taisho Pharma Co. Ltd, Medtronic Japan Co. Ltd, Sanwa Kagaku Kenkyusho Co. Ltd, Bayer Yakuhin, Ltd, Nipro Corp., Teijin Pharma Ltd, Arkray Inc., and Abbott Japan Co. Ltd, outside the submitted work. The other authors have nothing to disclose.

Informed consent: N/A.

Approval of the research protocol: The study was approved by the local ethics committee of Panasonic Health Insurance Organization.

Animal studies: N/A.

Approval date of registry and the registration no. of the study/trial: Approval data; March 1, 2021, Approval number: 2021-001.

Data sharing statement: The datasets of the current study are available on reasonable request.

REFERENCES

1. Doi Y, Ninomiya T, Hata J, et al. Two risk score models for predicting incident Type 2 diabetes in Japan. Diabetes Med 2012; 29: 107–114. doi:https://doi.org/10.1111/j.1464-5491.2011.03376.x.

2. Nanri A, Nakagawa T, Kuwahara K, et al. Development of risk score for predicting 3-year incidence of type 2 diabetes: Japan epidemiology collaboration on occupational health study. PLoS One 2015; 10: e0142779. doi:https://doi.org/10.1371/journal.pone.0142779.

3. Heianza Y, Arase Y, Hsieh SD, et al. Development of a new scoring system for predicting the 5 year incidence of type 2 diabetes in Japan: the Toranomon Hospital Health Management Center Study 6 (TOPICS 6). Diabetologia 2012; 55: 3213–3223. https://doi.org/10.1007/s00125-012-2712-0.

4. Mukai N, Doi Y, Ninomiya T, et al. Cut-off values of fasting and post-load plasma glucose and HbA1c for predicting Type 2 diabetes in community-dwelling Japanese subjects: the Hisayama Study. Diabetes Med 2012; 29: 99–106. doi: https://doi.org/10.1111/j.1464-5491.2011.03378.x.

5. Noda M, Kato M, Takahashi Y, et al. Fasting plasma glucose and 5-year incidence of diabetes in the JPHC diabetes study - suggestion for the threshold for impaired fasting glucose among Japanese. Endocr J 2010; 57: 629–637. https://doi.org/10.1507/endocrj.k10e-010.

6. Heianza Y, Arase Y, Fujihara K, et al. Longitudinal trajectories of HbA1c and fasting plasma glucose levels during the development of type 2 diabetes: the Toranomon Hospital Health Management Center Study 7 (TOPICS 7). Diabetes Care 2012; 35: 1050–1052. doi:https://doi.org/10.2337/dc11-1793.

7. Heianza Y, Harata S, Arase Y, et al. HbA1c 5-7-6-4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. Lancet 2011; 378: 147–155. doi:https://doi.org/10.1016/S0140-6736(11)60472-8.

8. American Diabetes Association. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care 2021; 44: S15–S33. doi:https://doi.org/10.2337/dc21-5002.
9. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2011; 34: S62–S69. https://doi.org/10.2337/dc11-S062.

10. Genuth S, Alberti KG, Bennett P, *et al*. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care* 2003; 26: 3160–3167. doi:https://doi.org/10.2337/diacare.26.11.3160.

11. Seino Y, Nanjo K, Tajima N, *et al*. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. *J Diabetes Investig* 2010; 1: 212–228. doi:https://doi.org/10.1111/j.2040-1124.2010.00074.x.

12. Kato M, Noda M, Suga H, *et al*. Fasting plasma glucose and incidence of diabetes — implication for the threshold for impaired fasting glucose: results from the population-based Omiya MA cohort study. *J Atheroscler Thromb* 2009; 16: 857–861. doi:https://doi.org/10.5551/jat.1792.

13. Kabeya Y, Shimada A, Yamasawa F, *et al*. Risk for future diabetes among individuals with high-normal glycaemia at 40 years of age. *Intern Med* 2012; 51: 2703–2708. doi:https://doi.org/10.2169/internalmedicine.51.7926.

14. Okada H, Hamaguchi M, Habu M, *et al*. Association between variability in body mass index and development of type 2 diabetes: Panasonic cohort study. *BMJ Open Diabetes Res Care* 2021; 9: e002123. doi:https://doi.org/10.1136/bmjdrcc-2021-002123.

15. Ogihara T, Mirmira RG. An islet in distress: β cell failure in type 2 diabetes. *J Diabetes Investig* 2010; 1: 123–133. doi: https://doi.org/10.1111/j.2040-1124.2010.00021.x.

16. Yabe D, Kuroe A, Watanabe K, *et al*. Early phase glucagon and insulin secretory abnormalities, but not incretin secretion, are similarly responsible for hyperglycemia after ingestion of nutrients. *J Diabetes Complications* 2015; 29: 413–421. doi:https://doi.org/10.1016/j.jdiacomp.2014.12.010.

17. Mitsui R, Fukushima M, Taniguchi A, *et al*. Insulin secretory capacity and insulin sensitivity in impaired fasting glucose in Japanese. *J Diabetes Investig* 2012; 3: 377–383. doi:https://doi.org/10.1111/j.2040-1124.2012.00201.x.

18. Ali MK, Bullard KM, Saydah S, *et al*. Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988–2014. *Lancet Diabetes Endocrinol* 2018; 6: 392–403. doi:https://doi.org/10.1016/S2213-8587(18)30027-5.

19. Pan Y, Chen W, Wang Y. Prediabetes and outcome of ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. *J Stroke Cerebrovasc Dis* 2019; 28: 683–692. doi:https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.11.008.

20. Huang Y, Cai X, Mai W, *et al*. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. *BMJ* 2016; 353: i5953. doi:https://doi.org/10.1136/bmj.i5953.

21. Ito C, Maeda R, Ishida S, *et al*. Correlation among fasting plasma glucose, two-hour plasma glucose levels in OGTT and HbA1c. *Diabetes Res Clin Pract* 2000; 50: 225–230. doi:https://doi.org/10.1016/s0168-8227(00)00187-x.

© 2021 The Authors. Journal of Diabetes Investigation published by AASD and John Wiley & Sons Australia, Ltd